Headlines about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.9837523842743 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern’s rankings:
- 4 Stocks To Watch: ABEO, IMMU, RTRX, VKTX (investing.com)
- Why Technical Analysis Matters on Viking Therapeutics, Inc. (VKTX) (wallstreetmorning.com)
- Equity Rundown: Viking Therapeutics, Inc. (NasdaqCM:VKTX), and Summit Midstream Partners, LP (NYSE:SMLP … (concordiareview.com)
- Beta Factor in Focus – Viking Therapeutics, (NASDAQ: VKTX) (stocksnewstimes.com)
- Viking Therapeutics (VKTX) Upgraded to Buy at ValuEngine (americanbankingnews.com)
A number of equities research analysts have weighed in on VKTX shares. Maxim Group restated a “buy” rating and issued a $8.00 target price on shares of Viking Therapeutics in a research report on Friday, February 2nd. Roth Capital set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 8th. BidaskClub downgraded Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Viking Therapeutics in a research report on Monday, March 26th. Finally, ValuEngine upgraded Viking Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.00.
VKTX traded up $0.32 during trading on Friday, reaching $5.38. The stock had a trading volume of 942,150 shares, compared to its average volume of 1,325,073. The company has a market capitalization of $244.99, a price-to-earnings ratio of -6.95 and a beta of 2.09. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $7.36.
Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. research analysts predict that Viking Therapeutics will post -0.44 earnings per share for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.